644 related articles for article (PubMed ID: 32276534)
1. The Landscape of Targeted Therapies in TNBC.
Vagia E; Mahalingam D; Cristofanilli M
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32276534
[TBL] [Abstract][Full Text] [Related]
2. Current landscape of personalized clinical treatments for triple-negative breast cancer.
Zhang J; Xia Y; Zhou X; Yu H; Tan Y; Du Y; Zhang Q; Wu Y
Front Pharmacol; 2022; 13():977660. PubMed ID: 36188535
[TBL] [Abstract][Full Text] [Related]
3. Precision Medicine and Triple-Negative Breast Cancer: Current Landscape and Future Directions.
Hossain F; Majumder S; David J; Miele L
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359640
[TBL] [Abstract][Full Text] [Related]
4. Triple-negative breast cancer: A run-through of features, classification and current therapies.
Manjunath M; Choudhary B
Oncol Lett; 2021 Jul; 22(1):512. PubMed ID: 33986872
[TBL] [Abstract][Full Text] [Related]
5. Targeted Therapeutic Strategies for Triple-Negative Breast Cancer.
Li Y; Zhan Z; Yin X; Fu S; Deng X
Front Oncol; 2021; 11():731535. PubMed ID: 34778045
[TBL] [Abstract][Full Text] [Related]
6. Clinical utility of genomic signatures for the management of early and metastatic triple-negative breast cancer.
Castellano G; Giugliano F; Curigliano G; Marra A
Curr Opin Oncol; 2023 Nov; 35(6):479-490. PubMed ID: 37621170
[TBL] [Abstract][Full Text] [Related]
7. [Recent therapeutic trends in triple-negative metastatic breast cancers: PARP inhibitors, immunotherapies and antibody-drug conjugates].
Dalenc F; Sarradin V; Nicolaï V; Franchet C; Ung M
Bull Cancer; 2021 Jan; 108(1):67-79. PubMed ID: 33422340
[TBL] [Abstract][Full Text] [Related]
8. Increased expression of biological markers as potential therapeutic targets in Saudi women with triple-negative breast cancer.
Sayed-Ahmed MM; Hafez MM; Al-Shabanah OA; Al-Rejaie SS; Aleisa AM; Al-Yahya AA; Alsheikh A; Al Diab AI; Al-Akeely MH
Tumori; 2013; 99(4):545-54. PubMed ID: 24326846
[TBL] [Abstract][Full Text] [Related]
9. Targeted Therapies in Triple-Negative Breast Cancer.
Marmé F; Schneeweiss A
Breast Care (Basel); 2015 Jul; 10(3):159-66. PubMed ID: 26557820
[TBL] [Abstract][Full Text] [Related]
10. Advances in the Management of Early-Stage Triple-Negative Breast Cancer.
Bhardwaj PV; Wang Y; Brunk E; Spanheimer PM; Abdou YG
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569851
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors.
Garufi G; Palazzo A; Paris I; Orlandi A; Cassano A; Tortora G; Scambia G; Bria E; Carbognin L
Expert Opin Pharmacother; 2020 Apr; 21(6):687-699. PubMed ID: 32052646
[TBL] [Abstract][Full Text] [Related]
12. Novel Agents for Metastatic Triple-Negative Breast Cancer: Finding the Positive in the Negative.
Vidula N; Ellisen LW; Bardia A
J Natl Compr Canc Netw; 2020 Oct; ():1-9. PubMed ID: 33075745
[TBL] [Abstract][Full Text] [Related]
13. Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies.
Xiong N; Wu H; Yu Z
Front Oncol; 2024; 14():1405491. PubMed ID: 38863622
[TBL] [Abstract][Full Text] [Related]
14. Triple-negative breast cancer and poly(ADP-ribose) polymerase inhibitors.
Park Y; Moriyama A; Kitahara T; Yoshida Y; Urita T; Kato R
Anticancer Agents Med Chem; 2012 Jul; 12(6):672-7. PubMed ID: 22263793
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities.
Ribeiro R; Carvalho MJ; Goncalves J; Moreira JN
Front Mol Biosci; 2022; 9():903065. PubMed ID: 36060249
[TBL] [Abstract][Full Text] [Related]
16. Research advances and new challenges in overcoming triple-negative breast cancer.
Zong Y; Pegram M
Cancer Drug Resist; 2021; 4(3):517-542. PubMed ID: 34888495
[TBL] [Abstract][Full Text] [Related]
17. Triumphs and challenges in exploiting poly(ADP-ribose) polymerase inhibition to combat triple-negative breast cancer.
Wooten J; Mavingire N; Damar K; Loaiza-Perez A; Brantley E
J Cell Physiol; 2023 Aug; 238(8):1625-1640. PubMed ID: 37042191
[TBL] [Abstract][Full Text] [Related]
18. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
19. Emerging drug targets for triple-negative breast cancer: a guided tour of the preclinical landscape.
Xie X; Lee J; Iwase T; Kai M; Ueno NT
Expert Opin Ther Targets; 2022 May; 26(5):405-425. PubMed ID: 35574694
[TBL] [Abstract][Full Text] [Related]
20. GLI1-targeting drugs induce replication stress and homologous recombination deficiency and synergize with PARP-targeted therapies in triple negative breast cancer cells.
Mani C; Tripathi K; Omy TR; Reedy M; Manne U; Palle K
Biochim Biophys Acta Mol Basis Dis; 2022 Feb; 1868(2):166300. PubMed ID: 34748904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]